Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial.
Twenty-four patients received either propranolol, lidoflazine (Clinium), or propranolol/lidoflazine combinations in a study designed to evaluate the effect of these drugs in angina pectoris. Five patients developed ventricular tachycardia when receiving either lidoflazine or lidoflazine and propranolol in combination; one of these patients died. In addition, one patient died suddenly while being treated with propranolol alone. Lidoflazine therapy was associated with a significant prolongation of the QT interval of the electrocardiogram. Lidoflazine either alone or in combination with propranolol, appears to induce ventricular tachycardia.
D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006321:Heart / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008013:Lidoflazine / Q000008:administration & dosage / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects*; D011433:Propranolol / Q000008:administration & dosage; D011897:Random Allocation; D013610:Tachycardia / Q000139:chemically induced* / Q000503:physiopathology
D010879:Piperazines; D011433:Propranolol; D008013:Lidoflazine